IN8bio, Inc. $INAB Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. trimmed its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 96.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 189,894 shares of the company’s stock after selling 5,506,308 shares during the period. Franklin Resources Inc. owned 6.27% of IN8bio worth $397,000 as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on INAB shares. Zacks Research raised IN8bio from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Mizuho set a $4.00 price target on IN8bio in a research report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IN8bio has an average rating of “Hold” and an average price target of $92.00.

IN8bio Stock Up 0.6%

Shares of INAB opened at $1.78 on Tuesday. The firm has a market cap of $7.51 million, a price-to-earnings ratio of -0.33 and a beta of 0.02. The business’s 50 day moving average is $1.95 and its two-hundred day moving average is $2.28. IN8bio, Inc. has a 52-week low of $1.53 and a 52-week high of $12.53.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.35. On average, equities analysts expect that IN8bio, Inc. will post -0.56 earnings per share for the current fiscal year.

IN8bio Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.